Skip to main content

TransMedics Group, Inc.

For the period ended Jun 30, 2026. Filed Aug 4, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 4, 2026

TMDX$90.95-3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows

(In thousands)

Six Months Ended June 30,
20262025
Cash flows from operating activities:
Net income$21,997$60,589
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization expense22,10612,868
Stock-based compensation expense18,55818,330
Deferred taxes4,866—
Non-cash interest expense9,2321,578
Non-cash operating lease expense1,229997
Unrealized foreign currency transaction (gains) losses652(1,473)
Loss on disposal of fixed assets—80
Changes in operating assets and liabilities:
Accounts receivable(19,948)(6,616)
Inventory(10,246)5,717
Prepaid expenses and other current assets(2,388)1,081
Other non-current assets(242)(4)
Accounts payable2,724(410)
Accrued expenses and other current liabilities(5,335)(2,413)
Deferred revenue225(192)
Operating lease liabilities(1,588)(1,378)
Net cash provided by operating activities41,84288,754
Cash flows from investing activities:
Purchases of property, plant and equipment(43,749)(36,113)
Net cash used in investing activities(43,749)(36,113)
Cash flows from financing activities:
Proceeds from issuance of common stock upon exercise of stock options3,2218,831
Proceeds from issuance of common stock in connection with employee stock purchase plan1,6881,286
Tax withholding payments related to net settlement of restricted stock units(177)—
Net cash provided by financing activities4,73210,117
Effect of exchange rate changes on cash and restricted cash(578)1,167
Net increase in cash and restricted cash2,24763,925
Cash and restricted cash, beginning of period488,866337,150
Cash and restricted cash, end of period$491,113$401,075
Supplemental disclosure of non-cash activities:
Transfers of inventory to property, plant and equipment$4,897$2,251
Purchases of property, plant and equipment included in accounts payable and accrued expenses$2,910$1,240
Operating lease liabilities arising from obtaining right-of-use assets$763$324
Finance lease liability arising from obtaining right-of-use assets$340,040$—
Purchases of property, plant and equipment included in other long-term liabilities$3,986$—
Reconciliation of cash and restricted cash:
Cash$472,675$400,575
Restricted cash18,438500
Total cash and restricted cash shown in the statement of cash flows$491,113$401,075
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.